Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

May 15, 2019 | Corporate News | English

Tecan to present at upcoming Investor Conferences in the United States

Männedorf, Switzerland, May 15, 2019 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at the following investor conferences in May:

UBS Global Healthcare Conference, New York, USA
Date: 21 May 2019, 8:00 am EDT (2:00 pm CET)
Presenter: Dr. Achim von Leoprechting, CEO, Tecan
Webcast live under the "Investor Relations" tab of Tecan's website www.tecan.com  
A replay of the webcast will be available after the presentation and will remain available for 90 days.

Berenberg Conference USA 2019, Tarrytown, USA
Date: 22 – 23 May 2019
Presentation: 22 May 2019, 11:45 am EDT (6:45 pm CET)
Presenter: Dr. Achim von Leoprechting, CEO, Tecan
No Webcast


About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2018, Tecan generated sales of CHF 594 million (USD 606 million; EUR 516 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).


For further information:

Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89